Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve The standalone and consolidated ....

Revenue declinedNet loss reportedEBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹1210.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.4%+5.7% vs market

Pharmaceuticals peers, median of 159sector-0.4%+4.7% vs sector

On the reaction day the stock moved 5.7 pts more than Nifty Microcap 250 and 4.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3-1.4+5.7-0.4+4.7

Next day

+2.5-4.5+6.9-2.0+4.4

+2.5-3.8+6.3-2.6+5.1

+0.5-3.6+4.1-2.1+2.6

+3.3-3.9+7.2-2.0+5.3

+4.8-5.2+10.0-2.6+7.4

+4.0-4.2+8.2-1.5+5.5

15d

+9.8-1.5+11.3-1.9+11.6

+9.1-3.1+12.2-1.4+10.5

+16.9+6.4+10.6+4.2+12.8

+13.7+8.3+5.3+6.1+7.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bharat Parenterals Ltd has informed BSE that its Board of Directors meeting is scheduled for May 18, 2026. The meeting will consider and approve the audited standalone and consolidated financial results for Q4 and the financial year ended March 31, 2026. The board will also review the audited annual financial statements and consider recommending a final dividend for FY 2025-26. Additionally, the trading window for designated persons has been closed since April 1, 2026, and will remain closed until 48 hours after the financial results are declared. This is a standard regulatory intimation under SEBI listing regulations.

Likely market impact

This is a routine board meeting notice for annual results announcement. No specific financial details or warnings are provided in this filing. Shareholders should expect Q4 and full-year results to be announced after May 18, 2026.

By the numbersConsolidated · Q4 FY26 vs Q4 FY25

	Q4 FY26	Q4 FY25	Change
Revenue	₹99.62 Cr	₹104.0 Cr	−4.2%
Operating profit	−₹12.00 Cr	−₹10.50 Cr	loss widened
Profit after tax	−₹8.16 Cr	−₹9.44 Cr	loss narrowed
EBITDA margin	-0.5%	2.1%	−2.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.